Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 11/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 10/20 | 0.47 |
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19779686 | 0.86 | CD274 (0.47) | MEN1RAB9AKMT2ACD274PDCD1 | |
| SCHEMBL19779430 | 0.85 | MEN1 (0.46) | MEN1RAB9AKMT2ACD274PDCD1 | |
| SCHEMBL19779676 | 0.81 | PDCD1 (0.69) | CD274PDCD1 | |
| SCHEMBL29893851 | 0.80 | PDCD1 (0.61) | MEN1RAB9AKMT2ASUCNR1CD274 | |
| SCHEMBL19785826 | 0.78 | SUCNR1 (0.50) | RAB9ASUCNR1CD274PDCD1BTK | |
| SCHEMBL19779554 | 0.76 | LMNA (0.47) | SUCNR1CD274PDCD1L3MBTL1ALDH1A1 | |
| SCHEMBL19779673 | 0.75 | CD274 (0.73) | CD274PDCD1 | |
| SCHEMBL19779689 | 0.75 | CD274 (0.47) | SUCNR1CD274PDCD1BTKL3MBTL1 | |
| SCHEMBL19779681 | 0.74 | CD274 (0.45) | SUCNR1CD274PDCD1BTKL3MBTL1 | |
| SCHEMBL13053955 | 0.73 | NPC1 (0.62) | MEN1RAB9AKMT2ACD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718605-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718605-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20210115025-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-04-22 | — | — | US | disclosed |
| US-20200283423-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-20180016260-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283423-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | MEN1 1546/4885RAB9A 2399/4885KMT2A 4066/4885 |
| US-11718605-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | MEN1 1546/4885RAB9A 2399/4885KMT2A 4066/4885 |
| US-20210115025-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | MEN1 1546/4885RAB9A 2399/4885KMT2A 4066/4885 |
| US-20180016260-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | MEN1 1546/4885RAB9A 2399/4885KMT2A 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.